Soufflé Therapeutics
CompanyUnited States
Soufflé Therapeutics develops one asset, in phase 1 (SFL-0821 in facioscapulohumeral muscular dystrophy). Mostly oligonucleotide acting on DUX4; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- Raised
- US$135m
- 1
- Trial
- 3
- Signals
Pipeline
1Silences DUX4 expression using RNA interference in muscle cells.
Phase 1, Oligonucleotide, DUX4, facioscapulohumeral muscular dystrophy
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Funding rounds and grants1
- Signals3
- Similar companies5